Fiscal year 2024 generic drug user fee calculations will incorporate a new workload-based model, but not account for all of the categories initially expected.
The US Food and Drug Administration committed to incorporating a capacity planning adjustment into GDUFA III fee calculations as part of the 2022 program reauthorization. Inspections are supposed to be part of the formula, but the FDA said in its
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?